Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Capital Expenditures: 2019-2024

Historic Capital Expenditures for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Dec 2024 value amounting to $143,000.

  • Arcutis Biotherapeutics' Capital Expenditures was N/A to $78,000 in Q2 2025 from the same period last year, while for Jun 2025 it was $835,000, marking a year-over-year change of. This contributed to the annual value of $143,000 for FY2024, which is 66.59% down from last year.
  • According to the latest figures from FY2024, Arcutis Biotherapeutics' Capital Expenditures is $143,000, which was down 66.59% from $428,000 recorded in FY2023.
  • Arcutis Biotherapeutics' Capital Expenditures' 5-year high stood at $995,000 during FY2021, with a 5-year trough of $143,000 in FY2024.
  • For the 3-year period, Arcutis Biotherapeutics' Capital Expenditures averaged around $301,333, with its median value being $333,000 (2022).
  • Its Capital Expenditures has fluctuated over the past 5 years, first spiked by 209.97% in 2021, then tumbled by 66.59% in 2024.
  • Yearly analysis of 5 years shows Arcutis Biotherapeutics' Capital Expenditures stood at $321,000 in 2020, then surged by 209.97% to $995,000 in 2021, then plummeted by 66.53% to $333,000 in 2022, then grew by 28.53% to $428,000 in 2023, then crashed by 66.59% to $143,000 in 2024.